A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Clinical trial NCT03022045 · COMPLETED
Trial details
- NCT number
- NCT03022045
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-26
- Primary completion
- 2017-09-17
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.